Business
Social Networks Logos
(Jaque Silva/Getty Images)
Weird Money

Cantor Fitzgerald wins big on Tether’s investment in Rumble

Despite Rumble consistently losing money quarter after quarter, the financial firm stands to benefit from the announcement.

Jack Raines

On December 20, Rumble, the conservative video-sharing platform, announced that it had received a $775 million “strategic investment” from stablecoin platform Tether. The terms of this investment were… interesting:

Investment: Tether has agreed to purchase 103,333,333 shares of Rumble Class A Common Stock at a price per share of $7.50, totaling $775 million in gross proceeds to Rumble. The Company will use $250 million of the proceeds to support growth initiatives.

Self Tender Offer: With the remaining gross proceeds, the Company will fund a self tender offer for up to 70 million shares of Rumble Class A Common Stock at a price per share of $7.50, net to the holder in cash. All holders of Rumble Class A Common Stock will be eligible to participate in the tender offer on the same terms. Certain Rumble stockholders have signed support agreements committing to tender 70 million shares in the aggregate, subject to the same proration and other terms of the tender offer that apply to all Rumble stockholders participating in the tender offer. Chris Pavlovski has committed to tender, and does not intend to sell more than 10 million shares of Class A Common Stock in the tender offer…

Timing: The investment and the tender offer are expected to close in the first quarter of 2025.

Basically, only $250 million of the $775 million is actually an investment in the business, where the cash actually hits Rumble’s balance sheet. The other $525 million is funding a “self tender offer,” meaning that Rumble will be buying up to 70 million shares of its stock back from investors at $7.50 per share, and the deal is expected to close in Q1 of next year.

A couple of things to note here: first, by any conventional metric, Rumble is just a really, really bad business. In Q3 2023, it lost $29 million on $18 million in revenue, and in Q3 2024 it lost $32 million on $25 million in revenue. Through the first nine months of 2024, Rumble lost $102 million, and even after accounting for noncash expenses, its operating cash flow was still -$75 million. In total, the company’s cash and cash equivalents shrank from $218 million at the beginning of the year to $131 million at the end of September.

Essentially, despite revenue growth, Rumble’s losses have continued to grow even faster, its cash burn is high, and at its current pace the company would be running low on cash within the next 12 months. Given its cash needs, it’s no surprise that it would look to raise outside financing to the tune of $775 million. What is surprising, however, is that Rumble is then using $525 million to… buy back shares at $7.50. For context, the stock closed at $7.19 on December 20, and it had been trading below $7 for most of the year. Rumble needs cash on its balance sheet, so spending that cash to buy back stock feels counterintuitive.

But there is an interesting wrinkle here: Cantor Fitzgerald, the investment bank and financial services firm led by Howard Lutnick (Trump’s secretary of commerce appointee), advised on this deal. Cantor Fitzgerald was also the sponsor behind the SPAC that took Rumble public, and it still owns more than 9 million shares of Rumble, which hasn’t done too well in the public markets. Per Rumble’s press release, “certain Rumble stockholders have signed support agreements committing to tender 70 million shares in the aggregate,” and it was interesting to me that the company advising on this transaction happens to own a sizable stake in the company as well, meaning that it could benefit from being one of the shareholders selling into the tender offer.

Yet the reaction of Rumble’s stock price after the news hit complicated things. Rumble was trading around $7 before the investment was announced. $7.50 would be a premium to that price, so it’s likely that plenty of shareholders would be happy with the $7.50 deal. But since this investment was announced, Rumble’s stock price has jumped from $7.19 to $16.70, as of this writing.

If you’re a Rumble shareholder, why would you sell to a tender offer at $7.50 when you could sell on the open market for $16 or more? You’d be leaving $9 and change on the table per share, so it wouldn’t surprise me if we saw this deal either get renegotiated or pulled altogether.

Regardless of what happens, Cantor Fitzgerald feels like the big winner here. The bank gets transaction fees, the value of its Rumble stake has now doubled, and it could possibly sell its stake at a premium to its recent stock price, renegotiate the terms of the tender to a higher price, or, at a minimum, retain its now more valuable stock. Not bad.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.